{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:16:36Z","timestamp":1790144196574,"version":"4.0.1"},"reference-count":133,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010875","name":"Amgen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014565","name":"Bausch Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019518","name":"Eli Lilly Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014554","name":"Janssen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009009","name":"Novartis Pharmaceuticals Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) are increasingly used to treat various cancers. Their use may result in immune\u2010related adverse events, including psoriasis. When managing psoriasis, induced or exacerbated by an ICI, there are concerns regarding immunosuppression from systemic agents for the treatment of psoriasis (saPs) and the potential impact on ICI efficacy. No direct, high\u2010level evidence exists to address these concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To address clinically relevant questions regarding the management of ICI\u2010mediated psoriasis (ICI\u2010Ps) with saPs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We convened a multidisciplinary panel of 15 international specialists in dermatology, oncology, immunology, and rheumatology. A Delphi process defined clinical concerns related to the systemic treatment of ICI\u2010Ps, focusing on the potential of saPs to impact ICI effectiveness. The saPs considered included biologics targeting tumour necrosis factor, interleukin (IL)\u201017, IL\u201012\/23 and IL\u201023, traditional systemic therapies (cyclosporine, methotrexate), small molecules targeting phosphodiesterase\u20104 or tyrosine kinase 2, systemic retinoids (acitretin), and systemic corticosteroids. A systematic review of the literature was supplemented with evidence supporting an inference\u2010based methodology to derive conclusions on the use of systemic therapies in patients with ICI\u2010Ps. The specialist panel rated the strength of the conclusions using a probabilistic scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After reviewing the totality of direct and indirect evidence, we drafted inference\u2010based conclusions and ascribed a level of support, focusing on the potential impact of saPs on ICI efficacy. This work provides a structured framework informing healthcare professional and patient discussions on the risks and benefits of using saPs in patients with cancer who experience ICI\u2010Ps.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although there is no direct evidence, we support the following conclusions: saPs may be used to treat ICI\u2010Ps without an appreciable loss of ICI effectiveness. Generally, it is not necessary to interrupt ICI therapy. When available, non\u2010steroid saPs are preferred over systemic corticosteroids for the treatment of psoriasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.20809","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T07:19:01Z","timestamp":1753082341000},"page":"1881-1894","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Systemic treatment of immune checkpoint inhibitor\u2010induced psoriasis: Inference\u2010based guidance"],"prefix":"10.1111","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim A.","family":"Papp","sequence":"first","affiliation":[{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"Alliance Clinical Research  Waterloo Ontario Canada"},{"name":"Department of Dermatology, Temerty Faculty of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Luis","family":"Puig","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital de la Santa Creu i Sant Pau  Barcelona Spain"},{"name":"Institut de Recerca Sant Pau (IR SANT PAU)  Barcelona Spain"},{"name":"Faculty of Medicine Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Beecker","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"University of Ottawa  Ottawa Ontario Canada"},{"name":"Division of Dermatology The Ottawa Hospital  Ottawa Ontario Canada"},{"name":"Ottawa Hospital Research Institute  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[{"name":"Gladman\u2010Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute University Health Network  Toronto Ontario Canada"},{"name":"Division of Rheumatology, Department of Medicine University of Toronto  Toronto Ontario Canada"},{"name":"Department of Laboratory Medicine and Pathobiology University of Toronto  Toronto Ontario Canada"},{"name":"Institute of Medical Science University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"Claveau","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Cancer Clinic, H\u00f4tel\u2010Dieu de Qu\u00e9bec, et Centre Int\u00e9gr\u00e9 de Canc\u00e9rologie Centre Hospitalier Universitaire de Qu\u00e9bec  Quebec City Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Medica Scientia Innovation Research (MEDSIR)  Barcelona Spain"},{"name":"Medica Scientia Innovation Research (MEDSIR)  Ridgewood New Jersey USA"},{"name":"Pangaea Oncology, Quiron Group International Breast Cancer Center (IBCC)  Barcelona Spain"},{"name":"Department of Medicine, Faculty of Biomedical and Health Sciences Universidad Europea de Madrid  Madrid Spain"},{"name":"IOB Madrid, Institute of Oncology Hospital Beata Mar\u00eda Ana  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Dutz","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Science, Faculty of Medicine University of British Columbia  Vancouver British Columbia Canada"},{"name":"Arthritis Research Canada  Vancouver British Columbia Canada"},{"name":"Division of Rheumatology Vancouver General Hospital  Vancouver British Columbia Canada"},{"name":"BC Children's Hospital Research Institute  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah I.","family":"Hornick","sequence":"additional","affiliation":[{"name":"Department of Dermatology Oregon Health &amp; Science University  Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalyn A.","family":"Juergens","sequence":"additional","affiliation":[{"name":"Department of Oncology, Juravinski Cancer Centre McMaster University  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Melosky","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology BC Cancer  Vancouver British Columbia Canada"},{"name":"Faculty of Medicine University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha B.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, MD Anderson Cancer Center University of Texas  Houston Texas USA"},{"name":"Department of Dermatology, Health Science Center University of Texas  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5605-3844","authenticated-orcid":false,"given":"Maxwell B.","family":"Sauder","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"Department of Dermatology, Temerty Faculty of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Sehdev","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre  Ottawa Ontario Canada"},{"name":"Division of Medical Oncology, The Ottawa Hospital University of Ottawa  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2585-6633","authenticated-orcid":false,"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[{"name":"Department of Oncodermatology Oncopole Claudius Regaud  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Snow","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine Dalhousie University  Halifax Nova Scotia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14613"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0897-9"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4318"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17855"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.02.030"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad257"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003066"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.048"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5476"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3003"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4129"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60030373"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.09.070"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000776"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2020.05.025"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.888377"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00866-z"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00642-5"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14011"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02141"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.137"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111548"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llac095"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41068"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14830"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031120"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00905-3"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20081811"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1711.1999.00795.x"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.434"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1163633"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.11181"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI184846"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00372-8"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008636"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042028"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60911-6"},{"key":"e_1_2_14_40_1","first-page":"252","article-title":"A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy","volume":"3","author":"Fujiwara Y","year":"2020","journal-title":"Cancer Drug Resist"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.11.007"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318247a4e7"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2023.101858"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00212-5"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00333-7"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.811829"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002293"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.076"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1883-1"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081721"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5570"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70254"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3181"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2021.108953"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544010-00003"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220597"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.928390"},{"key":"e_1_2_14_63_1","volume-title":"StatPearls","author":"Tapia C","year":"2023"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00915009"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-024-00448-4"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.120721"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12453"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1309349"},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3067126"},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2152322"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2020.12.006"},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0802-y"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00653-8"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01818"},{"key":"e_1_2_14_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0711-0"},{"key":"e_1_2_14_76_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000268"},{"key":"e_1_2_14_77_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0412-0"},{"key":"e_1_2_14_78_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000585"},{"key":"e_1_2_14_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac071"},{"key":"e_1_2_14_80_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159500"},{"key":"e_1_2_14_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02358-7"},{"key":"e_1_2_14_82_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-2524"},{"key":"e_1_2_14_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1162-y"},{"key":"e_1_2_14_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04146.x"},{"key":"e_1_2_14_85_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.727220"},{"key":"e_1_2_14_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58459-9"},{"key":"e_1_2_14_87_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028530"},{"key":"e_1_2_14_88_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030455"},{"key":"e_1_2_14_89_1","doi-asserted-by":"crossref","DOI":"10.1177\/2050313X231181035","article-title":"The use of interleukin\u201023 inhibitors to treat immune\u2010related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: a case series and review of the literature","volume":"11","author":"Fournier C","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"e_1_2_14_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102429"},{"key":"e_1_2_14_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110757"},{"key":"e_1_2_14_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2742"},{"key":"e_1_2_14_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-208249"},{"key":"e_1_2_14_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-177360"},{"key":"e_1_2_14_95_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002949"},{"key":"e_1_2_14_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.09.014"},{"key":"e_1_2_14_97_1","article-title":"IL\u201017 suppresses the therapeutic activity of cancer vaccines through the inhibition of CD8+ T\u2010cell responses","volume":"9","author":"Dadaglio G","year":"2020","journal-title":"Onco Targets Ther"},{"key":"e_1_2_14_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188758"},{"key":"e_1_2_14_99_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1703047"},{"key":"e_1_2_14_100_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040769"},{"key":"e_1_2_14_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2014.05.014"},{"key":"e_1_2_14_102_1","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_437_18"},{"key":"e_1_2_14_103_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003551","article-title":"Potential therapies for immune\u2010related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition","volume":"10","author":"Berg M\u2010HH","year":"2022","journal-title":"J Immunother Cancer"},{"key":"e_1_2_14_104_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"},{"key":"e_1_2_14_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111717"},{"key":"e_1_2_14_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.07.203"},{"key":"e_1_2_14_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103649"},{"key":"e_1_2_14_108_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001838"},{"key":"e_1_2_14_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"e_1_2_14_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"e_1_2_14_111_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003064"},{"key":"e_1_2_14_112_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1007394107"},{"key":"e_1_2_14_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02708.x"},{"key":"e_1_2_14_114_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.11.7553"},{"key":"e_1_2_14_115_1","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13346"},{"key":"e_1_2_14_116_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-217260"},{"key":"e_1_2_14_117_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw539"},{"key":"e_1_2_14_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2018.11.021"},{"key":"e_1_2_14_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.09.025"},{"key":"e_1_2_14_120_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3532"},{"key":"e_1_2_14_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.039"},{"key":"e_1_2_14_122_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00824-3"},{"key":"e_1_2_14_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.008"},{"key":"e_1_2_14_124_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06763-y"},{"key":"e_1_2_14_125_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.934093"},{"key":"e_1_2_14_126_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001901"},{"key":"e_1_2_14_127_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00136"},{"key":"e_1_2_14_128_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.10054"},{"key":"e_1_2_14_129_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407417"},{"key":"e_1_2_14_130_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"e_1_2_14_131_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216109"},{"key":"e_1_2_14_132_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726"},{"key":"e_1_2_14_133_1","unstructured":"Canadian Cancer Trials Group.A randomized phase III trial of the duration of anti\u2010PD\u20101 therapy in metastatic melanoma.2024. Clinical Trial Registration. Available from:https:\/\/clinicaltrials.gov\/study\/NCT02821013. Accessed 16 Nov 2024."},{"key":"e_1_2_14_134_1","first-page":"1","article-title":"CaSMO management of cutaneous toxicities associated with immune checkpoint inhibitors: a practical primer","author":"Sauder MB","year":"2022","journal-title":"Skin Ther Lett"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.20809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T10:41:20Z","timestamp":1763116880000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.20809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":133,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/jdv.20809"],"URL":"https:\/\/doi.org\/10.1111\/jdv.20809","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"2025-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}